PMID- 35242496
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20230917
IS  - 2210-7185 (Electronic)
IS  - 2210-7177 (Print)
IS  - 2210-7177 (Linking)
VI  - 2022
DP  - 2022
TI  - Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck 
      Lymphoma.
PG  - 4936099
LID - 10.1155/2022/4936099 [doi]
LID - 4936099
AB  - Statistical reports on non-Hodgkin's lymphoma (NHL) of the head and neck 
      combining clinical medicine with pathology are rare. To provide a basis for 
      prognosis prediction and individualized treatment, we will investigate the 
      clinicopathologic characteristics and prognosis of lymphoma in the head and neck 
      region. Four hundred sixty-one patients with NHL in the head and neck region 
      diagnosed through histological biopsy were retrospectively analyzed. Fluorescence 
      in situ hybridization (FISH) and immunohistochemistry (IHC) were performed in all 
      cases to evaluate the genetic status and protein expression levels. Patients were 
      followed up by telephone. The prevalence rate of primary extranodal NHL (PENHL) 
      in the head and neck region was 44.62% (166/372). The incidence of extranodal 
      lymphoma accounted for 36.66% (169/461) of all head and neck lymphomas. Among the 
      cases of PENHL of the head and neck, diffuse large B-cell lymphoma (DLBCL) 
      (60/76, 78.95%) and extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (21/24, 
      87.5%) were the most common subtypes originating from B-cell lymphoma (BCL) and 
      T-cell lymphoma (TCL), respectively. The most common sites of nodal and 
      extranodal onset were neck lymph nodes and the gastrointestinal tract, 
      respectively. The most common and primary locations of BCL and TCL were the 
      tonsils and nasal cavity, respectively. The 3-year survival rates of PENHL, 
      ENKTCL, and DLBCL of the head and neck were 42%, 28.57%, and 41.67%, 
      respectively, and the 5-year survival rates were 24%, 19.05%, and 20%, 
      respectively. Survival analysis showed that male sex was a risk factor (HR = 
      5.421; 95% CI, 1.164-25.267; p < 0.05) and that comprehensive treatment was a 
      protective factor (HR = 0.117; 95% CI, 0.025-0.545; p < 0.05) against extranodal 
      DLBCL in the head and neck region. Bone marrow involvement was a risk factor for 
      PENHL of the head and neck (HR = 5.072; 95% CI, 1.17-21.991; p < 0.05). The 
      purpose of this review is to show that PENHL of the head and neck with high 
      incidence deserves more attention, and a model of multidisciplinary diagnosis and 
      treatment should be adopted.
CI  - Copyright (c) 2022 Shufang Yan et al.
FAU - Yan, Shufang
AU  - Yan S
AUID- ORCID: 0000-0003-4408-0535
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Ma, Jiajia
AU  - Ma J
AUID- ORCID: 0000-0001-8678-2979
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Yang, Meihong
AU  - Yang M
AUID- ORCID: 0000-0002-0332-9739
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Liu, Bo
AU  - Liu B
AUID- ORCID: 0000-0002-3016-2049
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Li, Sijing
AU  - Li S
AUID- ORCID: 0000-0002-4354-7167
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Yang, Liuqing
AU  - Yang L
AUID- ORCID: 0000-0003-2844-903X
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Zhang, Qian
AU  - Zhang Q
AUID- ORCID: 0000-0003-3769-2912
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
AD  - Xinjiang Medical University, No. 567 North Shangde Road, Urumqi, The Xinjiang 
      Uygur Autonomous Region of China, 830011, China.
FAU - Li, Xinxia
AU  - Li X
AUID- ORCID: 0000-0002-0742-8072
AD  - Department of Pathology, The Tumor Hospital Affiliated to Xinjiang Medical 
      University, No. 789 Suzhou Dongjie, Urumqi, The Xinjiang Uygur Autonomous Region 
      of China, 830011, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220222
PL  - United States
TA  - Anal Cell Pathol (Amst)
JT  - Analytical cellular pathology (Amsterdam)
JID - 101541993
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - *Lymphoma, Non-Hodgkin/epidemiology/pathology
MH  - Male
MH  - Retrospective Studies
MH  - Survival Analysis
PMC - PMC8888118
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/03/05 06:00
MHDA- 2022/04/05 06:00
PMCR- 2022/02/22
CRDT- 2022/03/04 05:41
PHST- 2021/09/11 00:00 [received]
PHST- 2021/12/14 00:00 [revised]
PHST- 2022/01/22 00:00 [accepted]
PHST- 2022/03/04 05:41 [entrez]
PHST- 2022/03/05 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2022/02/22 00:00 [pmc-release]
AID - 10.1155/2022/4936099 [doi]
PST - epublish
SO  - Anal Cell Pathol (Amst). 2022 Feb 22;2022:4936099. doi: 10.1155/2022/4936099. 
      eCollection 2022.